Amritsar, NFAPost: Biocon Biologics has announced a global collaboration agreement with Voluntis to develop and distribute digital therapeutics supporting people with diabetes on biologics therapy.
This licensing agreement between Malaysian subsidiary Biocon Sdn. Bhd., and Voluntis will allow the company to offer therapeutic product ‘Insulia’ to type 2 diabetes patients in several markets across the globe, Biocon Biologics said in a statement today.
Biocon Biologics’ Insulia provides automated insulin dose recommendations enabling patients with diabetes to self-manage their condition and aids healthcare teams to remotely monitor their progress.
“The demand for at-home treatment and telemedicine solutions is dramatically increasing around the world, with select healthcare systems offering reimbursement for patients eligible for digital therapeutic solutions,” the company said.
It added that Biocon Biologics aspires to reimagine the patient ecosystem by developing a technology dependent operating model that enables personalisation of care, thus going beyond the product to reduce both the cost of the drug as well as the cost of administering the drug,
“We are delighted to collaborate with Voluntis for this unique digital therapeutic solution that has U.S. FDA clearance and a CE mark to help manage the treatment of Type 2 diabetes… We believe pairing our products with a digital therapeutic solution will help improve patient outcomes and reduce costs to healthcare systems in the long term. We remain committed to impact patients’ lives through innovative solutions,” Biocon Biologics Chief Executive Officer and Managing Director Christaine Hamacher said.
Boston and Paris-based Voluntis engages in creating digital therapeutics that allow people suffering from chronic conditions to manage their treatment by themselves every day.
